Showing 3771-3780 of 9357 results for "".
- Skin of Color Still Underrepresented Across Major Dermatology Image Searcheshttps://practicaldermatology.com/news/skin-of-color-still-underrepresented-across-major-dermatology-image-searches/2487573/Skin of Color (SOC) remains significantly underrepresented in image search results across major search engines, according to a recent Letter to the Editor published in the Journal of Drugs in Dermatology. Investigators building on earlier research in the area evaluated the first 5
- Global Integral Beauty Conference Marks Fifth Anniversary With Expanded International Programhttps://practicaldermatology.com/news/global-integral-beauty-conference-marks-fifth-anniversary-with-expanded-international-program/2487545/Global Integral Beauty (GIB) has announced that its 5th Global Integral Beauty Conference will be held on October 17, 2026, at the New York Marriott Marquis in New York, New York. Now entering its fifth year, the conference s
- AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Immunology Dealhttps://practicaldermatology.com/news/abbvie-to-acquire-apogee-therapeutics-in-109-billion-immunology-deal/2487547/AbbVie announced a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, a move the manufacturer said adds to its immunology pipeline and strengthens its presence in inflammatory diseases such as atopi
- Low Infection Risk Across Psoriasis Biologics Reported in Real-World Studyhttps://practicaldermatology.com/news/low-infection-risk-across-psoriasis-biologics-reported-in-real-world-study/2487541/A large real-world analysis published in the Journal of the American Academy of Dermatology indicates biologic therapies for psoriasis are associated with low overall infection risk, with ustekinumab and interleukin (IL)-23
- Paroxetine Linked to Neurovascular and Immune Proteomic Changes in Refractory Rosacea: Analysishttps://practicaldermatology.com/news/paroxetine-linked-to-neurovascular-and-immune-proteomic-changes-in-refractory-rosacea/2487517/A secondary analysis of a randomized clinical trial in JAMA Dermatology identified systemic proteomic changes associated with paroxetine treatment in patients with refractory erythematous rosacea, offering new insight into
- Intermittent Daily Isotretinoin Matches Alternate-Day Regimen in Grade 2 Acne Trialhttps://practicaldermatology.com/news/intermittent-daily-isotretinoin-matches-alternate-day-regimen-in-grade-2-acne-trial/2487522/A randomized controlled trial published in the Indian Journal of Medical Research found that an intermittent daily isotretinoin regimen was non-inferior to a continuous alternate-day regimen for the treatment of grade 2 facial acne vulgaris, while also offering lower treatment costs.¹ Rese
- Analysis Shows Long-Term Cost Impact of Psoriasis and Psoriatic Arthritishttps://practicaldermatology.com/news/analysis-highlights-long-term-cost-impact-of-psoriasis-and-psoriatic-arthritis/2487486/New research published in Dermatology and Therapy suggests the economic burden associated with psoriasis and psoriatic arthritis extends far beyond the diseases themselves and may reach hundreds of billions of dollars over a lifetime. Psoriatic Disease Comorbidities Drive Signifi
- Study Links Childhood Adversity to Mitochondrial Changes and Atopic Dermatitis Riskhttps://practicaldermatology.com/news/study-links-childhood-adversity-to-mitochondrial-changes-and-atopic-dermatitis-risk/2487465/A new study published in Psychoneuroendocrinology suggests that adverse childhood experiences (ACEs) may contribute to biologic changes associated with atopic disease, identifying mitochondrial DNA copy number (mtDNAcn) as a
- FDA Approves EBGLYSS 8-Week Dosings in Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-ebglyss-8-week-dosings-in-atopic-dermatitis/2487424/The US Food and Drug Administration (FDA) has approved an every-8-week maintenance dosing regimen for EBGLYSS® (lebrikizumab-lbkz) in adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic dermatitis, according to an
- Maternal Type 2 Diabetes Not Linked to Reduced AD Risk in Children: Studyhttps://practicaldermatology.com/news/maternal-type-2-diabetes-not-linked-to-reduced-ad-risk-in-children-study/2487400/New research suggests maternal type 2 diabetes mellitus (T2DM) does not independently influence the risk of atopic dermatitis (AD) in children. Researchers for a retrospective cohort study analyzed electronic medical and birth records from Clalit Health Services in Israel (n = 314,224 moth